Cross Labeling Oncology Drugs in Combination Regimens

2 November 2022 – FDA published final guidance on cross labeling oncology drugs for industry.

This guidance is to describe FDA’s current recommendations about including relevant information in labeling for oncology drugs approved for use in a combination regimen, including important considerations for cross labeling of these drugs.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /